Drug Target ReviewScientists Synthesize Pox Virus, Unleashing ControversyLaboratory Equipment“We believe this is the first complete synthesis of a poxvirus using synthetic biology approaches,” they write. The scientists, from the Canadian school as wel… Continue reading
Business Insider |
The hottest thing in cancer drug development just won a $9 billion endorsement
Business Insider Juno is known for its experimental, highly personalized cancer treatments called CAR T-cell therapy, which harnesses the body’s immune system to go after certain blood cancers. It’s part of a new field of cancer therapies that . In 2017, the FDA … Celgene to buy Juno for $9 billion to boost CAR–T expertiseReuters UPDATED: Celgene bags CAR–T player Juno in $9B buyout as biotech M&A suddenly explodesEndpoints News Celgene to buy Juno Therapeutics for about $9 billion – CNBC.comCNBC STAT –Business Wire (press release) –Zacks Investment Research –SEC.gov all 163 news articles » |
FierceBiotech |
Eureka nets $60M to take T–cell therapy into the clinic
FierceBiotech The FDA approved the first two CAR-T treatments for blood cancers—Novartis’ Kymriah and Kite and Gilead’s Yescarta—in 2017, but the agency still flags cytokine release syndrome and neurotoxicity as “significant safety issues” tied to this type of … Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor …Business Wire (press release) |